Roche is set to invest more than CHF3bn ($3.14bn) to develop a new research and development centre, upgrade infrastructure and renovate the existing office building at its Basel site in Switzerland.
The investment is planned for the next ten years, as the office and laboratory buildings on the site will not meet current day requirements, said Roche.
Roche CEO Severin Schwan said: "Roche is committed long-term to Switzerland and to Basel in its dual role as corporate headquarters and one of our most important sites worldwide.
"The entire value chain is represented in Basel. Employees from all parts of the company are making a vital contribution to Roche’s innovative strength, and we want to provide them with an attractive work environment."
Design of the new site was developed in collaboration with architects Herzog & de Meuron, which will include modern laboratories and offices on the main site.
The new research centre will include four integrated office and laboratory buildings of different heights, comprising 132m, 72m, 28m and 16m on the current site of building 74.
The new buildings will include 950 office and 950 laboratory workplaces, which are expected to go into service between 2021 and 2022.
The new office building in the interior of the firm’s site will be 205m tall, providing space for more than 1,700 office workplaces.
Roche intends to invest CHF700m ($734m) to upgrade existing buildings and for the infrastructure, including a logistics centre for energy consumption, safety, good manufacturing practice (GMP) guidelines and other requirements.
Roche Basel and Kaiseraugst site head Jürg Erismann said: "The planned consolidation of the existing industrial site will eliminate the need to build over green zones."
Image: Roche plans to develop a new research centre, upgrade infrastructure and renovate an existing office building at the Basel site. Photo: courtesy of F. Hoffmann-La Roche Ltd.